Reprod Biomed Online by Legro, Richard S et al.
Time Related Increase in Urinary Testosterone Levels and Stable 
Semen Analysis Parameters after Bariatric Surgery in Men
Richard S Legro, M.D.1, Allen R Kunselman, M.A.2, Juliana W Meadows, Ph.D.3, James S 
Kesner, Ph.D.3, Edward F Krieg Jr., Ph.D.3, Ann M Rogers, M.D.4, and Robert N Cooney, 
M.D.5
1Obstetrics and Gynecology, Pennsylvania State University College of Medicine, Hershey, 
PA17033, USA
2Public Health Sciences, Pennsylvania State University College of Medicine, Hershey, PA 17033, 
USA
3Division of Applied Research and Technology, National Institute for Occupational Safety and 
Health, Cincinnati, OH 45226, USA
4Surgery, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
5Surgery, SUNY Upstate Medical Center, Syracuse, NY 13210, USA
Abstract
We sought to determine the time-course in androgen and semen parameters in men after weight 
loss associated with bariatric surgery with a prospective cohort study of 6 male subjects, age 18-40 
years, meeting NIH bariatric surgery guidelines, conducted in 2005-2008, with study visits at 
baseline, then 1, 3, 6 and 12 months after surgery. All men had a Roux-en-y-Gastric-Bypass 
(RYGB) performed at Penn State Milton S. Hershey Medical Center. We collected at each visit 
biometric, questionnaire, serum, and urinary specimens as well as a semen analysis. Urinary 
integrated total testosterone levels increased significantly by 3 months after surgery, and remained 
elevated throughout the study. Circulating testosterone levels were also higher at 1 and 6 months 
after surgery, compared to baseline. Serum SHBG levels were significantly elevated at all time 
points post-operatively. After RYGB surgery, there were no significant changes in urinary 
estrogen metabolites (estrone 3-glucuronide) or serum estradiol levels, serial semen parameters, or 
male sexual function by questionnaire. This study supports the idea that a threshold of weight loss 
is necessary to improve male reproductive function by reversing male hypogonadism, manifested 
as increased testosterone levels. Further serial semen analysis results showed normal ranges for 
most parameters despite massive weight loss.
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INTRODUCTION
Obesity in men is associated with various reproductive abnormalities including 
hypogonadism (Schneider, et al., 1979), abnormalities in semen quality (Reis and Dias, 
2012), erectile dysfunction and diminished sexual desire (Hammoud, et al., 2009), and lower 
rates of paternity (Pauli, et al., 2008). These abnormalities are interrelated and may primarily 
stem from diminished androgen production and circulating levels (Hammoud, Gibson, Hunt, 
Adams, Carrell, Kolotkin and Meikle, 2009). Increased peripheral conversion of androgens 
into weak bioactive estrogens by excess adipose tissue may further exacerbate these 
symptoms (Schneider, Kirschner, Berkowitz and Ertel, 1979). This, in turn, analogous to 
polycystic ovary syndrome (PCOS) in women, can lead to a vicious circle of inappropriate 
sex steroid feedback upon the hypothalamic-pituitary-gonadal axis (Rebar, et al., 1976) and, 
in men, to a persistent hypogonadal state (George, et al., 2010).
Weight loss, both by diet and lifestyle or more profoundly after bariatric surgery, is 
associated with an improvement in male reproduction function. Studies have documented an 
increase and normalization of circulating testosterone levels, improved sexual function, but 
marked reduction in semen quality (Hammoud, Gibson, Hunt, Adams, Carrell, Kolotkin and 
Meikle, 2009, Lazaros, et al., 2012, Sermondade, et al., 2012). Most of these studies have 
been limited by a two-time point analysis, before and after intervention. Bariatric surgery 
provides a useful model to look at the effects of progressive weight loss over many time 
points and to better quantitate the relationship between weight loss and improvement in 
reproductive function. Further, there is a higher compliance with caloric restriction after 
bariatric surgery as compared with lifestyle studies due to restrictive effects of most bariatric 
surgery on ingestive behavior.
We have recently reported on this model in a cohort of women undergoing Roux en Y 
gastric bypass surgery (RYGB) surgery (Legro, et al., 2012). We conducted a similar pilot 
study in a group of males which we report here. As in the female study, we instituted a daily 
collection of urine to better understand changes in the excretion of sex steroid hormones 
(testosterone and estradiol metabolites) and to better define the effects of time and weight 
loss on reproductive function in men.
MATERIALS AND METHODS
Subjects
The protocol was reviewed and approved by the Institutional Review Board at Penn State 
College of Medicine. Men were recruited between 2005 and 2008 and studied for up to two 
years afterwards. All subjects gave written informed consent. Due to close-out of the grant, 
the study was terminated on January 1, 2010 and planned visits beyond this date could not 
be completed.
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Inclusion ages were 18-40 years. The 1991 NIH Guidelines for bariatric surgery were 
followed (1991): body mass index (BMI) above 40 kg/m2 or a BMI between 35 and 39.9 
kg/m2 with a weight-related health problem, such as diabetes or high blood pressure, and 
failed medical weight loss. Exclusion criteria included smoking or a history of alcohol or 
substance abuse. Subjects with obesity caused by hypothyroidism, Cushing’s syndrome, or 
genetic predisposition were excluded. We limited our study to subjects who had undergone 
RYGB surgery.
Visits
There were six visits planned during the study. A preoperative study visit was performed 
one month prior to gastric bypass surgery, then visits at 1, 3, 6, and 12 months after surgery. 
An additional visit was also planned at 24 months, but due to funding issues and closeout of 
the grant we were unable to obtain this visit in most participants and therefore do not report 
any data from this visit (Legro, et al., 2012). At each visit, a history and physical exam was 
performed, fasting blood was obtained in the morning, body composition was obtained via 
electroimpedance using a Tanita Model 310 Body Composition Analyzer, and daily urine 
collections were delivered. Subjects were instructed to collect first void daily urine samples 
from the preoperative visit until one month after, then for a month prior to each subsequent 
visit. Visits were scheduled to correspond with regular bariatric surgery follow-ups.
Before and 12 months after bariatric surgery, subjects filled out the Sexual Health Inventory 
for Men (SHIM), a brief multidimensional scale for assessing erectile dysfunction (ED) in 
men (Cappelleri and Rosen, 2005). SHIM scores for ED can range from 1 to 25, where 1-7 
is severe ED, 8-11 is moderate, 12-16 is mild to moderate, 17-21 is mild, and 22-25 is 
nonexistent ED.
Semen Analysis—Semen was collected at each visit after a period of abstinence ranging 
from 2 to 7 days. After liquefaction, volume was determined with a 5 mL pipette, 
concentration was determined. Concentration was determined by microscopic counting of 
sperm in a hemacytometer and motility by microscopic counting of motile sperm (at least 
100) with a microcell chamber. Morphology was determined using Spermac staining and 
strict Kruger criteria (Kruger et al, 1998).
Assays—Fasting serum collected in the a.m. from each visit was assayed for estradiol, 
total testosterone, and sex hormone binding globulin (SHBG) as previously reported (Legro, 
Dodson, Gnatuk, Estes, Kunselman, Meadows, Kesner, Krieg, Rogers, Haluck and Cooney, 
2012, Legro, et al., 2008). Every third daily urine sample collected was assayed. Urinary 
estrone 3-glucuronide (E13G) was measured in triplicate using a competitive double-
antibody time-resolved fluoroimmunoassay (Kesner, et al., 1994, Legro, Dodson, Gnatuk, 
Estes, Kunselman, Meadows, Kesner, Krieg, Rogers, Haluck and Cooney, 2012). Total 
testosterone was measured in duplicate in hydrolyzed urine samples using a 
radioimmunoassay (Siemens Coat-A-Count; cat no. TKTT5). The free androgen index (FAI) 
is calculated from measurable values for total T and SHBG, using the following equation: 
(FAI = Total testosterone in nmol/L / SHBG in nmol/L) X 100. Urinary E13G and total 
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testosterone values were divided by urinary creatinine concentrations to standardize for 
urine flow rate. All assays had a coefficient of variation less than or equal to 10%.
Statistical Analysis
Primary outcome—The primary outcomes were changes in the monthly serum and mean 
urinary total testosterone concentrations and semen analyses parameters at the various time 
points before and after surgery. We performed an a priori power analysis and arrived at a 
sample size of 20 men, which would provide at least 86% power to detect an effect size, |
μd|/σ, of 0.9 ng testosterone/mg Cr between any two visits using a two-sided, paired t-test 
with a family-wise type I error of 0.05. Secondary outcomes included changes in body 
weight and body composition, other circulating hormones, urinary estrogen levels, and 
erectile function. Due to limited funding we had to cease enrollment after we had enrolled 6 
subjects into this study.
Mixed-effects models were used to test for changes in the primary and secondary endpoints 
after surgery (Laird and Ware, 1982). A separate model was fit for each endpoint. Data were 
analyzed at 5 time points: before and 1, 3, 6, and 12 months after surgery. Contrasts were 
constructed to compare each post-surgery time point to the pre-surgical time point. Residual 
diagnostics from the mixed-effects models were examined to ensure the parametric 
modeling assumptions were met. All calculations were done with SAS® (Version 9.2, SAS 
Institute, Inc., Cary, North Carolina).
RESULTS
We screened 9 men and enrolled 6 subjects in the study. The median [minimum, maximum] 
age of the enrolled subjects was 37.5 [30, 40] years. Biometric, serum endocrine, and semen 
measurements before and after surgery are presented in Table I.
Urinary total testosterone levels, normalized to creatinine, increased significantly by 3 
months after RYGB surgery, compared to baseline, and remained elevated at subsequent 
visits through 12 months after surgery (P < 0.01) (Figure 1). Serum total testosterone levels 
were also higher at 1 month (P <0.01), 3 months (P=0.08), and 6 months (P < 0.01) after 
surgery compared to baseline (Table 2). Serum SHBG levels significantly increased by 1 
month post operatively, and remained elevated through 12 months after surgery (Table 2).
Neither urinary E13G nor circulating estradiol levels significantly changed after surgery. 
Urinary creatinine concentrations increased for 3 months after surgery (P<0.01), and then 
declined over time to baseline. Sperm concentrations tended to decrease 1 month after 
surgery (P=0.11), but then returned to pre-operative levels by 12 months. Relative to pre-
surgical assessment, male erectile function, as captured by the SHIM, tended to improve by 
12 months (13.5 ± 8.9 vs 18.0 ± 8.4, P = 0.13).
DISCUSSION
Our study showed a significant improvement in urinary total testosterone levels within 3 
months after RYGB surgery, which plateaued for the next 9 months despite continued 
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weight loss. This suggests a threshold effect of weight loss rather than a dose-response 
change in testosterone excretion with increasing weight loss. This was associated with a 
similarly sustained increase in serum levels of total testosterone and SHBG post-operatively. 
We noted no changes in semen parameters or estrogen concentrations in serum or urine. 
Although our sample size is small, our repeated measures of semen analysis from pre-
operative to 12 months post operatively are novel. As such they are reassuring about the 
persistence of normal semen parameters during massive weight loss. There was a 
nonsignificant trend towards enhanced male erectile function 12 months after surgery. And, 
as in our previous study of women (Legro et al., 2012), urinary creatinine levels increased 
for 3 months after surgery, which we attribute primarily to muscle loss during this period.
The strengths of our study include the detailed time-course for endocrine along with semen 
parameters in men after RYGB surgery. We expanded the endocrine assessment to include 
urinary measurements, which are valuable in epidemiological studies and even clinically. 
The weaknesses include the small sample size, which did not meet our statistically powered 
target sample size. Our inability to detect changes in additional biological endpoints after 
RYGB surgery is likely primarily due to limited power. Larger studies have supported an 
improvement in circulating sex steroid levels, increased SHBG levels and improved erectile 
function after bypass surgery (Hammond et al., 2009). The primary reason for the low male 
enrollment is that, compared to women, relatively few men elect RYGB surgery. But, a 
similar proportion of men (6 of 9 = 67%) and women (29 of 41 = 71%) who we screened for 
the study, were qualified and agreed to participate in our detailed studies of reproductive 
function before and after surgery (Legro et al., 2008).
Our findings are consistent with other detailed studies of significant weight loss in obese 
men, which also have noted primarily an improvement in androgen levels as well as 
increases in SHBG levels (Reis, et al., 2010, Strain, et al., 1988). The elevated urinary 
circulating testosterone levels are most likely due to increased gonadal production of 
testosterone, not to increased clearance of testosterone from the blood or reduced peripheral 
conversion of testosterone to estrogens. Increased testosterone levels are probably 
responsible for the trend towards improved male erectile function noted in our study and 
other larger studies of men after bariatric surgery (Hammoud, Gibson, Hunt, Adams, Carrell, 
Kolotkin and Meikle, 2009), despite the increase in SHBG that is likely related to decreased 
weight and insulin resistance. Improved mood and body image with weight loss may also be 
a factor as we have noted in women (Legro et al, 2012), but we did not track these in men.
These endocrine changes may, independent of estrogen levels, alter hypothalamic-pituitary-
gonadal function. Weight loss after bariatric surgery is associated with increased circulating 
levels of FSH (Facchiano, et al., 2013, Pellitero, et al., 2012, Reis, Favaro, Barreiro, de 
Oliveira, Chaim, Fregonesi and Ferreira, 2010, Strain, Zumoff, Miller, Rosner, Levit, Kalin, 
Hershcopf and Rosenfeld, 1988) and occasionally LH (Facchiano, Scaringi, Veltri, Samavat, 
Maggi, Forti, Luconi and Lucchese, 2013). Some have reported that serum estradiol levels 
decrease with BMI in men (Facchiano, Scaringi, Veltri, Samavat, Maggi, Forti, Luconi and 
Lucchese, 2013, Hammoud, Gibson, Hunt, Adams, Carrell, Kolotkin and Meikle, 2009, 
Pellitero, Olaizola, Alastrue, Martinez, Granada, Balibrea, Moreno, Serra, Navarro-Diaz, 
Romero and Puig-Domingo, 2012).
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Although other studies of semen quality after bariatric surgery have had larger samples sizes 
(up to 20 subjects) (Reis, Favaro, Barreiro, de Oliveira, Chaim, Fregonesi and Ferreira, 
2010), most studies have assessed 10 subjects or less and lack multiple time points of 
observation beginning prior to surgery. Thus there is a tendency to publication bias with 
smaller case series showing dramatic reductions in sperm parameters after surgery (Lazaros, 
Hatzi, Markoula, Takenaka, Sofikitis, Zikopoulos and Georgiou, 2012, Sermondade, 
Massin, Boitrelle, Pfeffer, Eustache, Sifer, Czernichow and Levy, 2012). While our study, 
with more frequent sampling of semen parameters, initially detected a numerical reduction 
in sperm concentration after surgery, this trend was neither statistically significant nor 
sustained. Another recent larger study also failed to detect reduced sperm concentrations 
after 4 and 24 months (Reis, Favaro, Barreiro, de Oliveira, Chaim, Fregonesi and Ferreira, 
2010). Larger studies are needed to more reliably assess the effects of weight loss on this 
outcome.
Our study, though small, supports an improvement in male reproductive function after 
RYGB surgery as evidenced by increased serum and urinary testosterone levels. Further 
study of reproductive changes and especially effects on male fertility are needed.
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Urinary concentrations (means + SE) of E13G, total testosterone and creatinine in men 
before and 1, 3, 6 and 12 months after RYGB surgery. E13G and testosterone levels are 
corrected for creatinine. Asterisks indicate differences (P<0.0001) between post-surgical and 
pre-surgical measurements. N = 6 at all times except n=5 at 12 months.
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Table 1

























Biometric n=6 n=6 n=6 n=6 n=5
















































































Semen n=4 n=4 n=4 n=4 n=3
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Table 2


























Biometric n=6 n=6 n=6 n=5
 Weight (kg) −19 (−25,−14) <0.01 −32 (−39,−24) <0.01 −46 (−56,−37) <0.01 −55 (−69,−41) <0.01
 BMI (kg/m2) −6 (−9,−3) <0.01 −9 (−13,−5) <0.01 −12 (−17,−6) <0.01 −14 (−21,−7) <0.01
 Fat % −1 (−6,3) 0.53 −11 (−17,−4) <0.01 −16 (−24,−8) <0.01 −17 (−27,−7) <0.01
Endocrine n=6 n=6 n=6 n=5
 Serum Estradiol (pmol/L) 19 (−15,53) 0.25 22 (−22,66) 0.31 18 (−33,69) 0.46 −26 (−85,34) 0.38
 Serum Testosterone (nmol/L) 5 (2,8) <0.01 4 (0,8) 0.08 6 (2,11) 0.01 4 (−1,10) 0.12
 Serum SHBG (nmol/L) 24 (15,32) <0.01 17 (5,29) 0.01 21 (6,37) 0.01 25 (5,46) 0.02
 Free Androgen Index −12 (−21,−2) 0.02 −9 (−22,3) 0.14 −3 (−19,14) 0.74 −2 (−24,20) 0.83
Semen n=4 n=4 n=4 n=3
 Vol. (mL) 0.6 (−1.7,2.9) 0.52 0.9 (−1.4,3.2) 0.40 0.3 (−1.9,2.5) 0.77 0.0 (−2.2,2.2) 0.99
 Concentration (Million/mL) −42 (−92,8) 0.09 −35 (−104,34) 0.29 −15 (−103,73) 0.71 33 (−88,154) 0.57
 Motility % −2 (−27,22) 0.84 8 (−22,39) 0.56 2 (−33,37) 0.90 10 (−31,51) 0.60
 Normal Morphology % 3 (−15,22) 0.71 3 (−14,20) 0.69 −2 (−21,16) 0.79 −3 (−22,15) 0.70
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